Brazil‘s health watchdog agency Anvisa decided to approve this Thursday the emergency immunization of children and teenagers without comorbidities between 6 and 17 years old against COVID-19 with the CoronaVac vaccine.
The board unanimously followed the recommendation presented by the agency’s general manager of medicines, Gustavo Mendes, that for this target audience this immunizer can reduce the occurrence of serious cases, hospitalizations, and deaths by COVID-19
This means that the agency partially agreed with the request made by the Butantan Institute, linked to the São Paulo government.
The original request was to use CoronaVac applied to children and teenagers between 3 and 17 years old, regardless of whether they have any type of immunity compromise. But the board understood that not enough data was presented to guarantee security for this extended public.
For this age group, CoronaVac will be inoculated in two doses, with an interval of 28 days.
The approval was possible because of a phase 3 study carry out with children in Chile. Last August, when Butantan Institute first presented the request the agency rejected the use of the immunizer for the pediatric public.
The CoronaVac vaccine – developed by the Chinese laboratory Sinovac, which has Butantan as a partner in Brazil – received authorization for emergency use in adults and was the first to be used in Brazil, with strong use at the beginning of last year. Later, it was supplanted by other immunizers.
(Translated by LABS)